RECRUITING

Exercise to Improve Brain Health in Older African Americans

Conditions

Aging Alzheimer Disease Healthy Aging Cognitive Change

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to test the effects of different types of exercise on brain health and Alzheimer's risk in older African Americans. Specifically, the main question\[s\] it aims to answer are: * What is the effect of a Cardio-Dance Fitness (CDF) vs. a Strength, Flexibility, and Balance (SFB) intervention on a cognitive marker of Alzheimer's risk, generalization? * What is the effect of the CDF vs. SFB intervention on a fMRI biomarker of Alzheimer's, neural flexibility, and do improvements in neural flexibility mediate improvements in generalization? * Do ABCA7 genotypic variations moderate the efficacy of the CDF vs. SFB intervention for reducing Alzheimer's risk? Participants will undergo-- at baseline and post-test-- health assessments, cognitive tests, and structural and functional magnetic resonance imaging (fMRI), and a blood-draw to assess Alzheimer's risk biomarker levels.

Official Title

Determinants of Individual Differences in the Efficacy of Aerobic Exercise to Improve Brain Health and Reduce Alzheimer's Disease Risk in Older African Americans

Quick Facts

Study Start:2023-04-20

Study Completion:2027-08-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05597124

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:60 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* self-identify as either African American or Black; * be age 60 or older; * able to speak, read, and understand English; * available over the study period; independently ambulatory (i.e., not needing a wheelchair, walker, or cane); * meet criteria for low levels of physical activity (less than 60 minutes per week) based on the International Physical Activity Questionnaire (IPAQ-short version); * scoring 28-35 (inclusive) on the Telephone Interview for Cognitive Status Modified (sensitivity \[43%\], specificity \[94%\] for lower threshold; sensitivity \[93%\], specificity \[42%\] for upper threshold)55. * scoring 20-26 (inclusive) on the Montreal Cognitive Assessment (MoCA) during the in-person screening * have clearance to participate from their primary care physician, with oversight of all our patient health under the guidance of our physician-scientist Co-I, William Hu, Chief of Cognitive Neurology at Rutgers.	* color-blindness (because some of our tasks utilize color as a cue); * any diagnosed neurological disorder (including headaches and peripheral neuropathy); diagnosed or self-reported non-neurological conditions that likely affect MTL outcomes, such as, major depressive disorder (or a Geriatric Depression Scale-Short Form score ≥ 5), schizophrenia, delusional disorder, schizoaffective disorder or significant psychiatric symptoms that could impair the completion of the study (e.g., psychosis), substance-related and addictive disorders (or treatment in past five years), chemotherapy or radiation treatment for cancers, planning to undergo general anesthesia during the study period; * exercise contraindications, such as, orthopedic complications, myocardial infarction, coronary artery bypass grafting, angioplasty or other cardiac condition in the past year, current treatment for congestive heart failure, angina, uncontrolled arrhythmia, deep vein thrombosis (DVT) or another cardiovascular event, and uncontrolled hypertension with resting systolic or diastolic blood pressures \> 180/110 mmHg.

Inclusion Criteria

Exclusion Criteria

* self-identify as either African American or Black;
* be age 60 or older;
* able to speak, read, and understand English;
* available over the study period; independently ambulatory (i.e., not needing a wheelchair, walker, or cane);
* meet criteria for low levels of physical activity (less than 60 minutes per week) based on the International Physical Activity Questionnaire (IPAQ-short version);
* scoring 28-35 (inclusive) on the Telephone Interview for Cognitive Status Modified (sensitivity \[43%\], specificity \[94%\] for lower threshold; sensitivity \[93%\], specificity \[42%\] for upper threshold)55.
* scoring 20-26 (inclusive) on the Montreal Cognitive Assessment (MoCA) during the in-person screening
* have clearance to participate from their primary care physician, with oversight of all our patient health under the guidance of our physician-scientist Co-I, William Hu, Chief of Cognitive Neurology at Rutgers.

* color-blindness (because some of our tasks utilize color as a cue);
* any diagnosed neurological disorder (including headaches and peripheral neuropathy); diagnosed or self-reported non-neurological conditions that likely affect MTL outcomes, such as, major depressive disorder (or a Geriatric Depression Scale-Short Form score ≥ 5), schizophrenia, delusional disorder, schizoaffective disorder or significant psychiatric symptoms that could impair the completion of the study (e.g., psychosis), substance-related and addictive disorders (or treatment in past five years), chemotherapy or radiation treatment for cancers, planning to undergo general anesthesia during the study period;
* exercise contraindications, such as, orthopedic complications, myocardial infarction, coronary artery bypass grafting, angioplasty or other cardiac condition in the past year, current treatment for congestive heart failure, angina, uncontrolled arrhythmia, deep vein thrombosis (DVT) or another cardiovascular event, and uncontrolled hypertension with resting systolic or diastolic blood pressures \> 180/110 mmHg.

Contacts and Locations

Study Contact

Bernadette A. Fausto, PhD

CONTACT

(973) 944-0775

bernadette.fausto@rutgers.edu

Jennifer Greene, MPH

CONTACT

(973) 353-2257

jag644@rutgers.edu

Principal Investigator

Mark A. Gluck, PhD

PRINCIPAL_INVESTIGATOR

Rutgers, The State University of New Jersey - Newark campus

Study Locations (Sites)

Rutgers, The State University of New Jersey - Newark campus

Newark, New Jersey, 07102

United States

Collaborators and Investigators

Sponsor: Rutgers, The State University of New Jersey

Mark A. Gluck, PhD, PRINCIPAL_INVESTIGATOR, Rutgers, The State University of New Jersey - Newark campus

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-04-20

Study Completion Date2027-08-31

Study Record Updates

Study Start Date2023-04-20

Study Completion Date2027-08-31

Terms related to this study

Additional Relevant MeSH Terms

Aging
Alzheimer Disease
Healthy Aging
Cognitive Change